What question did this study set out to answer?

To provide evidence-based guidance and consensus recommendations for clinicians on the diagnosis, risk assessment, and therapeutic management of nonalcoholic fatty liver disease.

July 17, 2017HepatologyOpen Access

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

View Full Paper

Ask AI

Bookmark

To provide evidence-based guidance and consensus recommendations for clinicians on the diagnosis, risk assessment, and therapeutic management of nonalcoholic fatty liver disease.
A multidisciplinary expert panel conducted a formal review and analysis of published clinical literature identified through a Medline search up to August 2016.
Evidence quality was evaluated using standard health practice guideline methodologies alongside expert consensus for areas lacking definitive clinical trial data.
Weight loss of at least 3% to 5% improves hepatic steatosis, whereas achieving a 7% to 10% reduction is necessary to improve histological features of nonalcoholic steatohepatitis, including inflammation and fibrosis.
Liver biopsy remains the definitive diagnostic standard for identifying advanced disease, while non-invasive biomarkers and elastography effectively stratify low- versus high-risk advanced fibrosis.
Pioglitazone and vitamin E show histological efficacy in biopsy-proven steatohepatitis and may be considered in selected populations, whereas metformin and omega-3 fatty acids are not recommended for treating liver disease directly.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Practice guidance outlines diagnostic and therapeutic strategies for fatty liver disease, highlighting structured weight loss and targeted pharmacotherapies.

Cite This Study

Chalasani et al. (2017) studied this question.

synapsesocial.com/papers/69d56df375589c71d767d215 https://doi.org/10.1002/hep.29367

View Full Paper

Ask AI

Bookmark

Implication

Practice guidance outlines diagnostic and therapeutic strategies for fatty liver disease, highlighting structured weight loss and targeted pharmacotherapies.

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Key Points

Discussion

Implication

Cite This Study

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider